Published in Int J Oncol on November 01, 1998
Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol (2001) 2.20
Beta-catenin--a linchpin in colorectal carcinogenesis? Am J Pathol (2002) 2.18
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol (2001) 1.94
Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia (2009) 1.05
Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am J Pathol (2000) 1.04
ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis (1999) 1.01
Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin Exp Metastasis (2006) 0.98
A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation. Clin Exp Metastasis (2004) 0.92
Proteolysis of CCN1 by plasmin: functional implications. Cancer Res (2005) 0.91
Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol (2008) 0.89
The urokinase plasminogen activator receptor promotes efferocytosis of apoptotic cells. J Biol Chem (2009) 0.88
The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma. Breast Care (Basel) (2008) 0.87
Sialylated Lewis x antigen bearing glycoproteins in human plasma. J Proteome Res (2010) 0.87
(4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase. Proc Natl Acad Sci U S A (2000) 0.85
Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1. Clin Exp Metastasis (2003) 0.84
Cell surface antigens in renal tumour cells: detection by immunoluminescence and enzymatic analysis. Br J Cancer (2001) 0.83
Improved biochemical strategies for targeted delivery of taxoids. Bioorg Med Chem (2007) 0.79
The voltage-dependent anion channel (VDAC) binds tissue-type plasminogen activator and promotes activation of plasminogen on the cell surface. J Biol Chem (2012) 0.79
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors. Radiol Oncol (2015) 0.78
Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase. Mol Cancer (2013) 0.78
An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue. J Cancer (2014) 0.78
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Carcinogenesis (2015) 0.78
cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer. Oncotarget (2016) 0.78
The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells. Clin Exp Metastasis (2006) 0.77
Binding of tissue-type plasminogen activator to the glucose-regulated protein 78 (GRP78) modulates plasminogen activation and promotes human neuroblastoma cell proliferation in vitro. J Biol Chem (2014) 0.77
High tPA-expression in primary melanoma of the limb correlates with good prognosis. Br J Cancer (2000) 0.76
Human retinal pigment epithelial lysis of extracellular matrix: functional urokinase plasminogen activator receptor, collagenase, and elastase. Trans Am Ophthalmol Soc (2002) 0.76
Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: role of oxygenation status and tumour size. Br J Cancer (2002) 0.75
Exploring the potential of a structural alphabet-based tool for mining multiple target conformations and target flexibility insight. PLoS One (2017) 0.75
Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1. PLoS One (2017) 0.75
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 13.59
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood (1995) 4.12
Purification of profilin from Saccharomyces cerevisiae and analysis of profilin-deficient cells. J Cell Biol (1990) 3.42
Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit (2009) 3.32
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene (2000) 2.71
stevor and rif are Plasmodium falciparum multicopy gene families which potentially encode variant antigens. Mol Biochem Parasitol (1998) 2.58
Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol (2000) 2.58
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother (2007) 2.49
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol (2000) 2.28
The dissociation of discriminative and conditioned reinforcing functions of stimuli with changes in deprivation. J Exp Anal Behav (1968) 2.24
Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation (1996) 2.20
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res (2001) 2.06
Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med (1998) 2.05
Influence of Nitrate and Ammonia on Photosynthetic Characteristics and Leaf Anatomy of Moricandia arvensis. Plant Physiol (1982) 2.02
Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol (1999) 2.02
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat (1993) 1.97
Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2011) 1.88
European principles of haemophilia care. Haemophilia (2008) 1.84
Molecular characterization of a carbon transporter in plastids from heterotrophic tissues: the glucose 6-phosphate/phosphate antiporter. Plant Cell (1998) 1.82
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost (1997) 1.78
Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci U S A (1997) 1.76
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst (2001) 1.71
[Reliable micromethod for determination of the protein content in tissue homogenates]. Acta Biol Med Ger (1975) 1.69
11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood (1997) 1.69
BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood (1994) 1.68
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. Gastroenterology (2001) 1.66
EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol (2009) 1.58
Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells. J Immunol (1981) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet (1994) 1.56
Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia (2010) 1.51
Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ (2002) 1.50
Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost (2008) 1.48
Assessment of ketorolac as an adjuvant to fentanyl patient-controlled epidural analgesia after radical retropubic prostatectomy. Anesthesiology (1993) 1.47
LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett (1999) 1.46
Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost (1991) 1.46
Comparison of standard endoscopic submucosal dissection (ESD) versus an optimized ESD technique for the colon: an animal study. Endoscopy (2009) 1.44
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res (1992) 1.44
Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia (2010) 1.41
Optimized differential diagnosis of breast lesions by combined B-mode and color Doppler sonography. Ultrasound Obstet Gynecol (1997) 1.41
Quality of life measurement in children and adolescents: issues, instruments, and applications. J Clin Psychol (2001) 1.40
Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. Haemophilia (2007) 1.40
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
Isolated spastic paraparesis leading to diagnosis of Friedreich's ataxia. J Neurol Neurosurg Psychiatry (2000) 1.40
[Argon plasma surgery (APC) in the upper aerodigestive tract. Initial results]. HNO (1998) 1.39
A case-control study on the psychological aspects and coping in haemophilic patients. Haemophilia (2004) 1.39
Morphine antagonises action of prostaglandin in neuroblastoma and neuroblastoma times glioma hybrid cells. Nature (1975) 1.38
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol (1994) 1.36
Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res (1994) 1.36
Construction and characterization of a Plasmodium vivax genomic library in yeast artificial chromosomes. Genomics (1997) 1.34
A review of parameters for the bioelectrical characterization of breast tissue. Ann N Y Acad Sci (1999) 1.34
Sequence analysis and protein import studies of an outer chloroplast envelope polypeptide. Proc Natl Acad Sci U S A (1990) 1.33
Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol (1999) 1.30
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost (2008) 1.29
Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem (1991) 1.29
Expression of the functional mature chloroplast triose phosphate translocator in yeast internal membranes and purification of the histidine-tagged protein by a single metal-affinity chromatography step. Proc Natl Acad Sci U S A (1993) 1.28
The HYP2 gene of Saccharomyces cerevisiae is essential for aerobic growth: characterization of different isoforms of the hypusine-containing protein Hyp2p and analysis of gene disruption mutants. Mol Gen Genet (1993) 1.28
Intersection of group I CD1 molecules and mycobacteria in different intracellular compartments of dendritic cells. J Immunol (2000) 1.27
High resolution BrainPET combined with simultaneous MRI. Nuklearmedizin (2011) 1.26
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem (2008) 1.25
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet (1989) 1.22
Role of tissue factor in adhesion of mononuclear phagocytes to and trafficking through endothelium in vitro. Blood (1998) 1.21
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst (1996) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol (1998) 1.19
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res (2001) 1.19
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol (2001) 1.16
Methylated genes as new cancer biomarkers. Eur J Cancer (2009) 1.16
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia (2009) 1.16
Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med (2008) 1.15
The 'prespore-like cells' of Dictyostelium have ceased to express a prespore gene: analysis using short-lived beta-galactosidases as reporters. Development (1994) 1.15
[Reduction and fixation of fractures of the neck of the radious be centro-medullary pinning. Original technic]. Rev Chir Orthop Reparatrice Appar Mot (1980) 1.14
Expression of the triose phosphate translocator gene from potato is light dependent and restricted to green tissues. Mol Gen Genet (1993) 1.14
Left superior vena cava: revisited. Eur Heart J Cardiovasc Imaging (2012) 1.13
Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol (1996) 1.13
[Problems posed by carciovascular endoscopy. Experimental results]. Presse Med (1966) 1.13
Regulation of the oxidative response of human granulocytes to chemoattractants. No evidence for stimulated traffic of redox enzymes between endo and plasma membranes. J Biol Chem (1985) 1.13